NANOPARTICLE DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR PXD101 FACILITATES BLADDER CANCER CELL UPTAKE AND CYTOTOXICITY

被引：0
|
作者：
Kaimakliotis, Hristos Z.
Martin, Darryl T.
Hoimes, Christopher J.
Cheng, Christopher C.
Liu, Jingchun
Kelly, Wm. Kevin
Tew, Gregory N.
Saltzman, W. Mark
Weiss, Robert M.
机构：
来源：
JOURNAL OF UROLOGY | 2011年 / 185卷 / 04期
关键词：
D O I：
10.1016/j.juro.2011.02.1180
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
1358
引用
收藏
页码：E542 / E542
页数：1
相关论文
共 50 条
  • [21] Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101
    Plumb, JA
    Finn, PW
    Williams, RJ
    Bandara, MJ
    Romero, MR
    Watkins, CJ
    La Thangue, NB
    Brown, R
    MOLECULAR CANCER THERAPEUTICS, 2003, 2 (08) : 721 - 728
  • [22] A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors
    Hansen, M
    Gimsing, P
    Rasmussen, A
    Jensen, PB
    Knudsen, LM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 225S - 225S
  • [23] Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
    Amanda Cashen
    Mark Juckett
    Alcee Jumonville
    Mark Litzow
    P. J. Flynn
    John Eckardt
    Betsy LaPlant
    Kristina Laumann
    Charles Erlichman
    John DiPersio
    Annals of Hematology, 2012, 91 : 33 - 38
  • [24] The histone deacetylase inhibitor PXD101 synergises with established chemotherapeutics to inhibit tumor cell proliferation and upregulate apoptosis in vitro.
    Ritchie, J
    Tumber, A
    Edwards, N
    Finn, P
    Jensen, PB
    Sehested, M
    McLaughlin, F
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6105S - 6106S
  • [25] The histone deacetylase inhibitor PXD101 inhibits the growth of human ovarian and colon tumour xenografts in vivo.
    Plumb, JA
    Williams, RJ
    Finn, PW
    Bandara, MJ
    Romero, MR
    Watkins, CJ
    La Thangue, NB
    Brown, R
    BRITISH JOURNAL OF CANCER, 2002, 86 : S16 - S16
  • [26] Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Warren, Katherine E.
    McCully, Cindy
    Dvinge, Henrik
    Tjornelund, Jette
    Sehested, Maxwell
    Lichenstein, Henri S.
    Balis, Frank M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) : 433 - 437
  • [27] Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Katherine E. Warren
    Cindy McCully
    Henrik Dvinge
    Jette Tjørnelund
    Maxwell Sehested
    Henri S. Lichenstein
    Frank M. Balis
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 433 - 437
  • [28] Plasma and cerobrospinal fluid (CSF) pharmacokinetics of the histone deacetylase (HDAC) inhibitor, PXD101, in non-human primates
    Warren, Katherine E.
    McCully, Cindy M.
    Dvinge, Henrik
    Sehested, Maxwell
    Tjornelund, Jette
    Lichenstein, Henri S.
    Balis, Frank M.
    CANCER RESEARCH, 2006, 66 (08)
  • [29] Growth inhibition of renal cancer cells by histone deacetylase inhibitors, suberoylanilide hydroxamic acid (SAHA) and PXD101
    Min, Gyeong Eun
    Hwang, Jung Jin
    Yoo, Changhee
    Kim, Mi-Joung
    Kim, Yong-Sook
    Song, Kanghyon
    Kim, Seong Cheol
    Kwon, Taek Min
    Park, Jong Yeon
    Ahn, Tai Young
    Kim, Choung-Soo
    JOURNAL OF UROLOGY, 2008, 179 (04): : 40 - 40
  • [30] PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors
    Li, Jingyao
    Li, Xiaoyang
    Wang, Xue
    Hou, Jinning
    Zang, Jie
    Gao, Shuai
    Xu, Wenfang
    Zhang, Yingjie
    CHEMICAL BIOLOGY & DRUG DESIGN, 2016, 88 (04) : 574 - 584
12345